论文部分内容阅读
目的评估洛铂联合替吉奥治疗晚期胃癌的临床疗效及不良反应。方法用方案治疗48例晚期胃癌患者,具体用法:洛铂35mg/m2,静脉滴注2h,第1d给药;替吉奥40mg/m2,每日2次口服,第1~14d。每21d为1周期,连用2周期后进行影像学检查和实验室检查评价疗效和不良反应。结果48例患者总有效率46.7%,CR2例(4.4%)、PR19例(42.2%)、SD18例(40.0%)、PD6例(13.3%),疾病控制率86.7%。骨髓抑制Ⅲ~Ⅳ度占37.7%(17/45),Ⅲ度以下消化道反应37.8%(17/45),腹疼腹泻8.9%(4/45)。结论洛铂联合替吉奥治疗晚期胃癌疗效确切,不良反应轻,耐受性好,值得临床推广应用。
Objective To evaluate the clinical efficacy and side effects of lobaplatin combined with tigiao in the treatment of advanced gastric cancer. Methods Forty-eight patients with advanced gastric cancer were treated with the regimen: Losoplatin 35mg / m2, intravenous drip 2h, administered on the 1st day, 40mg / m2 for the Giovan, orally twice daily for 1-14 days. Every 21d for a cycle, even after 2 cycles of imaging and laboratory tests to evaluate the efficacy and adverse reactions. Results The total effective rate was 46.7% in 48 patients, CR2 (4.4%), PR19 (42.2%), SD18 (40.0%), PD6 (13.3%) and disease control rate 86.7%. Myelosuppression Ⅲ ~ Ⅳ degrees accounted for 37.7% (17/45), Ⅲ degree below the gastrointestinal reaction 37.8% (17/45), abdominal pain and diarrhea 8.9% (4/45). Conclusions The combination of lobaplatin and tegaserod for the treatment of advanced gastric cancer has definite curative effect, light adverse reactions and good tolerability. It is worthy of clinical application.